On Tuesday, Shares of Align Technology Inc. (NASDAQ:ALGN), gained 3.59% to $56.15.
Align Technology, declared that the Company will report first quarter 2015 financial results on Thursday, April 23, 2015 after the close of market. Financial results will be released at 4:00 p.m. ET (1:00 p.m. PT) and will be accessible on the Investor Relations section of the Company’s website at http://investor.aligntech.com.
Align Technology, Inc. designs, manufactures, and markets a system of clear aligner therapy, intra-oral scanners, and computer-aided design and computer-aided manufacturing (CAD/CAM) services for use in dentistry, orthodontics, and dental records storage in the United States and internationally.
Shares of Incyte Corporation (NASDAQ:INCY), gained 3.48% to $109.18, during its last trading session, hitting its highest level.
Incyte Corporation, declared that eleven abstracts detailing its emerging development pipeline will be presented at the 2015 American Association for Cancer Research (AACR) Annual Meeting in Philadelphia, PA. These abstracts comprise characterizations of Incyte’s FGFR, BRD and PIM inhibitors as potential targeted therapies for cancer, in addition to data supporting the potential immuno-therapeutic activity of the company’s portfolio of JAK and PI3Kδ inhibitors alone and in combination, counting with epacadostat, Incyte’s leading IDO1 inhibitor.
The Company also offered an updated presentation of its clinical portfolio, which now comprises INCB54828, a potent and selective FGFR inhibitor and INCB50465, a PI3Kδ inhibitor, which entered clinical trials in Q1 2015 for solid tumors and B-lymphoid malignancies. INCB54329, a bromodomain inhibitor, is predictable to enter clinical trials in Q2 2015 in hematology oncology. Additional first-line pancreatic cancer patients are being recruited into the expansion cohort of JAK1-selective inhibitor INCB39110 in combination with gemcitabine and nab-paclitaxel to continue the dose optimization phase of this proof-of-concept trial. Incyte therefore no longer anticipates to initiate a pivotal trial of INCB39110 in first-line pancreatic cancer during 2015.
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics primarily for oncology.
At the end of Tuesday’s trade, Shares of ETSY INC (NASDAQ:ETSY), gained 3.41% to $25.75.
ETSY, declared the closing of its initial public offering and the exercise in full of the underwriters’ option to purchase an additional 2,499,999 shares from selling stockholders.
After the underwriters’ exercise of the option to purchase additional shares, a total of 19,166,665 shares were sold at the price to the public of $16.00 per share for a total of $306,666,640 in aggregate gross proceeds, which comprised of the sale of 5,833,332 shares by selling stockholders. Etsy will not receive any proceeds from the sale of shares by the selling stockholders.
Goldman, Sachs & Co. and Morgan Stanley & Co. LLC acted as joint book-running managers for the offering. Allen & Company LLC, Loop Capital Markets LLC and The Williams Capital Group, L.P. acted as co-managers.
Etsy, Inc. operates online and offline marketplaces to buy and sell handmade items, vintage goods, and craft supplies. Its platform connects sellers and buyers to sell or buy products for art, home and living, mobile accessories, jewelry, wedding, and others.
Finally, Scholastic Corporation (NASDAQ:SCHL), ended its last trade with 3.34% gain, and closed at $43.94, hitting its highest level.
On April 1, Scholastic Corporation declared the publication of The Holocaust: The Story of Nazi Persecution and the Influence of Hate on Humanity, a nonfiction reader for Grades 7-10 that covers everything educators need to teach students about the Holocaust. Created by the editors of the company’s award-winning classroom magazines, the reader is a reliable nonfiction resource designed to engage and inform students about the timeline, history, participants, and influence of the Holocaust.
The Holocaust: The Story of Nazi Persecution and the Influence of Hate on Humanity is a 32-page book which comprises:
- High-quality informational texts on the history of the Holocaust, in addition to other genocides and the ways young people can assist fight hate recently;
- Interviews with survivors and accounts from perpetrators and bystanders;
- Historic photography and primary source excerpts that give students deeper insight into this global tragedy;
- Maps and eye-opening infographics perfect for the Social Studies classroom;
- Online teaching resources counting a 16-page Teaching Guide with lesson plans and correlations to the Common Core State Standards
- Glossary of important vocabulary and key terms; and
- Activities and reflections to assist build comprehension.
Scholastic Corporation operates as a children’s publishing, education, and media company in the United States. The company’s Children’s Book Publishing and Distribution segment publishes and distributes children’s books, media, and interactive products through school-based book clubs and book fairs, and the trade channel.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
